TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication

Table 2 Antitumor efficacy of Paclitxel against MDA-MB-431 pBabe and pTRF2 xenografts

Treatment groups	Tumor volume inhibition^a	Stable disease^b	Complete response^c	ILS^d (%)	Body weight loss^e (%)
MDA-MB-231 pBabe+PACLI	57	3/5	0/5	33	2
MDA-MB-231 pTRF2+PACLI	78	4/	1/5	63	2

Following transplantation, tumors were allowed grow for 7 days to about 250 mm³ before initiation of treatment (day 1). Mice were treated with PACLI iv at 20 mg/kg at day 1 and 8
^aTumor volume inhibition was calculated as the nadir of the effect by the following formula: (tumor volume treated mice/tumor volume untreated mice-1) x 100
^bStable disease was defined as the maintaining of the same tumor volume, after the initiation of treatment, for at least three weeks
^cComplete response was defined as disappearance of tumor for at least two weeks
^dIncrease of life survival. The animals were euthanized for ethical reasons when tumors reached a mean of 1.2 cm³ in volume and the time of euthanization was recorded as the time of death
^eThe percentage of body weight loss was calculated after the initiation of treatment

ISSN: 1756-9966